in a double-blind double-placebo crossover study naproxen ( 500-750 mg daily ) was found to be equivalent to phenylbutazone ( 400-600 mg daily ) in the control of disease activity in 20 patients suffering from ankylosing spondylitis during a two times 5-week trial period .
C0027396
naproxen
C0038013
ankylosing spondylitis